CAJ | 학술논문

ST段抬高型心肌梗死（ST-elevation myocardial infarction ， STEMI）是临床上常见的心血管危重症，直接经皮冠脉介入治疗（percutaneous coronary inter -vention， PCI）是目前公认最有效的再灌注疗法，能降低梗死后缺血事件，有助于靶血管血运重建。研究表明，血小板在心肌微血管灌注中发挥重要作用， PCI围手术期抗血小板治疗已成为提高疗效和降低并发症的重要手段。血小板膜糖蛋白Ⅱb/Ⅲa （GP Ⅱb/Ⅲa）是血小板聚集的最终共同途径中的关键因素，特别是在动脉血栓形成过程中起着重要作用，因此阻断GP Ⅱb/Ⅲa 受体是治疗和预防血栓性疾病的重要措施。糖蛋白Ⅱb/Ⅲa受体拮抗剂（GPIs）是最有效的抗血小板药物，其作为ST段抬高型心肌梗死患者行直接PCI期间的辅助治疗方法。本文回顾了近年来关于比较冠脉内使用和静脉内使用GPIs疗效的研究进展。
ST단태고형심기경사（ST-elevation myocardial infarction ， STEMI）시림상상상견적심혈관위중증，직접경피관맥개입치료（percutaneous coronary inter -vention， PCI）시목전공인최유효적재관주요법，능강저경사후결혈사건，유조우파혈관혈운중건。연구표명，혈소판재심기미혈관관주중발휘중요작용， PCI위수술기항혈소판치료이성위제고료효화강저병발증적중요수단。혈소판막당단백Ⅱb/Ⅲa （GP Ⅱb/Ⅲa）시혈소판취집적최종공동도경중적관건인소，특별시재동맥혈전형성과정중기착중요작용，인차조단GP Ⅱb/Ⅲa 수체시치료화예방혈전성질병적중요조시。당단백Ⅱb/Ⅲa수체길항제（GPIs）시최유효적항혈소판약물，기작위ST단태고형심기경사환자행직접PCI기간적보조치료방법。본문회고료근년래관우비교관맥내사용화정맥내사용GPIs료효적연구진전。
ST-elevation myocardial infarction (ST elevation myocardial infarction , STEMI) is a common clinical cardiovascular critically ill.Direct percutaneous coronary intevention (percutaneous coronary system -vention, PCI) is now recognized as the most effective reperfusion therapy , which can reduce ischemic events after infarction and help to target vessels reascularization .Studies have shown that platelets play an important role in the myocardial microvascular perfusion ; PCI perioperative antiplatelet therapy has become an important means to improve the curative effect and can reduce complications .Platelet membrane glycoprotein Ⅱb/Ⅲa ( GPⅡb/Ⅲa) is the key factor in the final of the common way of platelet aggregation and especially plays an important role in the process of arterial thrombosis so that blocking the GP Ⅱb/Ⅲa receptor is one of the important measures in the treatment and prevention of thrombotic diseases .Glycoprotein Ⅱb/Ⅲa receptor antagonist ( GPIs) is the most effective antiplatelet drugs .This paper reviews the curative effects of intravascular and intravenous use of glycoprotein Ⅱb/Ⅲa receptor antagonist ( GPIs) in recent years .